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Available online 23 April 2016Background:Diabetes and cancer are public health issuesworldwide; studies have shown that diabetes is related
to increased breast cancer mortality. The purpose of this study was to examine associations between HbA1C and
obesity with tumor stage and mortality among breast cancer patients.
Methods: Data for 82 patients with breast cancer (36–89 years of age, diagnosed /treated 1999–2009) were
provided by the University of Arkansas for Medical Sciences (UAMS) Data Trust Warehouse. Survival time was
estimated from start date of service to date of last follow-up or date of death. The Kaplan–Meiermethod provided
analysis of survival curves for two groups of HbA1C (HbA1C b 6.5% vs HbA1C ≥ 6.5%) and two groups of BMI
(BMI b 30 vs BMI ≥ 30 kg/m2); survival curves were compared using log-rank tests. Associations between
HbA1C and BMI, and between HbA1C and tumor stage were determined by chi-square.
Results: The relationship between tumor stages andHbA1Cwas not statistically signiﬁcant (X2=0.093, p=0.47,
df= 1). The relationship between obesity and HbA1Cwas statistically signiﬁcant (X2= 6.13, p= 0.013, df= 1).
Log-rank tests did not show statistically signiﬁcant differences between survival curves (HbA1C curves, p = 0.4;
Obesity curves, p = 0.09).
Conclusion: While there was a statistically signiﬁcant association between HbA1C and obesity, there were no
signiﬁcant associations found with this analysis. However, there are clinically meaningful relationships based
on observed trends. Future directions for research may involve exploring a larger sample of patients and
the role of therapeutic regimens on blood sugar control and BMI of breast cancer patients and inﬂuence on
cancer prognosis.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Obesity1. Introduction
Breast cancer is themost commonmalignant tumor among women,
and of all cancers, it is the second leading cause ofmortality inwomen in
the US. Estimates for 2016 predicted that 246,660womenwere likely to
be diagnosed with invasive breast cancer and that 40,450 women were
likely to die from breast cancer [1]. The rate of mortality from breast
cancer has declined due to improvements in early detection and treat-
ment [1]. Early detection of the cancer and evaluation of comorbidities
result in prompt and relevant treatment that improves breast cancer
survival and ultimately saves lives.
Type 2 diabetesmay increase the risk of cancer [2–5], is considered a
common comorbidity present in a considerable number of breast cancer
patients and correlates with poor clinical outcomes [6–9]. Furthermore,
diabetes may alter the efﬁcacy of treatment in breast cancer patients
affecting drug response and survival endpoints [8,10–12]. Therefore un-
derstanding the associations between diabetes and cancer developmentd Nutrition, 4301 W. Markham
. This is an open access article underwill contribute toward improving cancer screening and assessment
practices. The aim of this study was to examine associations between
HbA1C and obesity with tumor stage and mortality among breast
cancer patients.
2. Methods
2.1. Data source
Data for this project came from i2b2 (informatics for integrating
biology and the bedside), a large computerized data base at UAMS
[13].The dataset consisted of de-identiﬁed secondary data and was
exempt from review by the UAMS Institutional Review Board (IRB).
2.2. .Study population
A cohort was formed including subjects diagnosed with breast dur-
ing the years of 2001–2009. African-American (AA) and Caucasian
women who were ≥18 years of age at diagnosis, and who had at
least one HbA1C on ﬁle were included. Subjects with documented
pathological tumor stage, BMI and dates of ﬁrst and last clinic visitsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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clinic. The ﬁrst visit was deﬁned as the date the patient started
service at the clinic and the last follow-up was deﬁned as the last visit.
Life /death status was deﬁned according to the Social Security Death
Index updated in 2013.
2.3. HbA1C, BMI and tumor stage classiﬁcation
HbA1C was classiﬁed in two groups (normal versus high) with a
cut-point value of 6.5% [14,15]. BMI was classiﬁed into 2 groups; non-
obese was deﬁned as BMI b 30 kg/m2 and obese was deﬁned as
BMI ≥ 30 kg/m2. Tumor stage was classiﬁed as low or high based on
the TNM classiﬁcation system (low stages 0–I; high stages II–III) [16].
2.4. Data analysis and statistics
Descriptive statistics including frequencies were used to describe
study participant characteristics including age, BMI, HbA1C levels, and
tumor stage.
The Kaplan–Meier method provided descriptive analysis of survival
curves for the two HbA1C groups and for two BMI groups (BMI b 30
versus BMI ≥ 30 kg/m2); survival curves were compared using log-
rank tests. Associations between HbA1C and other variables including
BMI and tumor stage were determined by chi-square test. All statistical
analyses were performed using Excel (Microsoft Corporation, Seattle,
WA), Prism 5 (GraphPad Software, Inc., LaJolla, CA), and IBM SPSS
Statistics Version 22 (IBM Corp., Armonk, NY) software.
3. Results
The characterization of the studied population is shown in Table 1.
The age of the study population ranged from 36 to 89 years (mean =
60). Sixty-two subjects were ≥50 years of age (categorized as
post-menopausal) and 20 were b50 years of age (categorized as
pre-menopausal). The study population consisted of 56% Caucasian
and 41.5% AA women.
BMI of the study population ranged from18.73 kg/m2 to 53.81 kg/m2
(mean = 31.72 ± 7.5 kg/m2). Forty-two subjects (51.2%) were
classiﬁed as obese (BMI ≥ 30 kg/m2), and 40 (48.8%) were non-obese
(BMI b 30 kg/m2). The levels of HbA1C varied from 4.8% to 17% with a
mean of 6.9%. Forty-six subjects (54.9%) were grouped into the normalTable 1
Characterization of the studied population.
Number (%) Mean (±SD)
Age
b 50 20 (24) 60
≥ 50 62 (76)
Total 82 (100)
Race
White 46 (56)
African American 36 (44)
BMI
b 30 40 (49) 25.6 (±2.72)
≥ 30 42 (51) 37.3 (±5.7)
Total 82 (100) 31.7 (±7.5)
Hb1Ac
b 6.5 46 (55) 5.7 (±0.5)
≥ 6.5 36 (45) 8.3 (±2.6)
Total 82 (100) 6.9 (±2.2)
Tumor stage
Stage 0 13 (16)
Stage I 28 (34)
Stage II 27 (33)
Stage III 14 (17)
Low stage (Stages 0 & I) 38 (46.3)
High stage (Stages II & III) 44 (53.7)HbA1C category (b6.5%) and 36 (45.1%) were grouped into the high
HbA1C category (≥6.5%).
Thirty-eight subjects were categorized as having low stage tumors
(46.3%) and 44 were categorized with high stage tumors (53.7%).
A Chi-square test indicated no signiﬁcant association between HbA1C
category and tumor stage (x2 = 0.093, p = 0.47, df = 1).
We further examined the association of high HbA1C on tumor
survival. The Kaplan–Meier method provided descriptive analysis of
survival curves for the two HbA1C groups (Fig. 1) and for the two BMI
groups (Fig. 2). Survival curves were compared using log-rank tests,
which determined there were no statistically signiﬁcant differences
between survival curves (HbA1C curves, p = 0.4; Obesity curves,
p = 0.09).
Result of chi-square analysis (Table 2) testing the association be-
tween obesity and HbA1C was statistically signiﬁcant (X2 = 6.126,
p = 0.013, df = 1). The percentage of obese patients is clearly larger
in the high HbA1C group compared to normal HbA1C group; the per-
centage of non-obese patients is lower in high HbA1Cgroup compared
to normal HbA1C group (Fig. 3).
4. Discussion
Diabetes and cancer are two major public health issues worldwide
and many studies have shown that diabetes is related to increased
cancer mortality [8,17,18]. According to a review completed by Long
and colleagues [19], many studies have shown dysregulation in cellular
metabolism may associate with resistance to cancer treatment drugs.
Various factors, including insulin, insulin-like growth factor (IGF), and
inﬂammatory cytokines, may link diabetes to breast cancer mortality.
In the study reported here, we examined the association of HbA1C as
an indicator of blood glucose control with tumor stage and patient
mortality among 82 patients diagnosed with breast cancer. We used
tumor stage as an indicator of aggressiveness and did not ﬁnd a statisti-
cally signiﬁcant association between HbA1C levels and tumor stage.
These data suggest that blood glucose control as measured by HbA1C
is not associated with cancer stage in this population. Our results
contradict other studies showing diabetes correlates with late stage
diagnosis [9,20]. Peairs et al. [9] performed a meta-analysis examining
the effect of pre-existing diabetes on outcomes of breast cancer.
Among 4 datasets included in their analysis, 3 showed an association
between diabetes and diagnosis at late stage. One study did not ﬁnd
an association between diabetes and breast cancer stage. Peairs et al.
[9] suggest that a lack of association between diabetes and breast cancer
stage could be due to large number of samples with missing stage in
the study. However, a study investigating associations between type
2 diabetes and colon cancer found that, despite a negative association
between diabetes and survival rate, there was not an association
between diabetes and tumor stage [21]. Together, the data suggest
that involvement of diabetes with mortality in breast cancer patients
may be due to non-breast cancer speciﬁc causes.
According to results reported here, there was not a statistically sig-
niﬁcant difference between survival curves for the different HbA1CFig. 1. Survival analysis was performed using Kaplan–Meier method. Log rank test was
used to statistically compare the curves and p value is shown.
Fig. 2. Survival analysis was performed using Kaplan–Meier method. Log rank test was
used to statistically compare the curves and p value is shown.
Fig. 3. Visual representation chi-square analysis demonstrating the distribution of obese
and non-obese patients across high and normal HbA1C groups.
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elevated HbA1C levels in plasma was independently associated
with higher mortality in breast cancer survivors [20]. Lack of statistical
signiﬁcance in the current study is most likely due to small sample
size that results in a low-power study. Despite our small sample size,
we observed a potentially clinically relevant decrease in survival of
patients with HbA1C ≥ 6.5%. However, such a decrease is not accompa-
nied with high tumor stage, suggesting that deaths could be unrelated
to cancer.
As expected, we observed a positive and statistically signiﬁcant
association between obesity and HbA1C, which may suggest the
HbA1C groups (≥6.5% vs b6.5%) actually represent individuals with
differing mortality risk, and is worth additional investigation involving
a larger sample size. Obesity is a major factor associated with type 2
diabetes [22] that may also affect breast cancer survival [23]. Result of
the current study leans toward poorer survival in the obese group,
which is in harmony with published data [23].5. Study limitations
Limitations of the current study included a small sample size, and
unavailability of prognostic factors and cancer-speciﬁc survival data.6. Conclusions
Breast cancer has a low mortality rate and survivors are living
longer; therefore, there is need for studies with a longer follow-up
period. Future directions for research may involve exploring a larger
sample of patients and the role of therapeutic regimens on blood
sugar control and BMI of breast cancer patients and inﬂuence on
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